Nyxoah (NASDAQ:NYXH) PT Lowered to $18.00

Nyxoah (NASDAQ:NYXH) had its price objective trimmed by HC Wainwright from $22.00 to $18.00 in a research report sent to investors on Friday, Benzinga reports. The firm currently has a buy rating on the stock.

NYXH has been the subject of a number of other research reports. Stifel Nicolaus reiterated a buy rating and set a $27.00 price target on shares of Nyxoah in a report on Wednesday, May 15th. Cantor Fitzgerald reduced their target price on Nyxoah from $18.00 to $17.00 and set an overweight rating for the company in a research note on Wednesday, May 15th. Oppenheimer dropped their price target on Nyxoah from $20.00 to $15.00 and set an outperform rating on the stock in a research note on Wednesday, May 15th. Finally, Piper Sandler lifted their price objective on shares of Nyxoah from $15.00 to $20.00 and gave the stock an overweight rating in a research report on Wednesday, March 6th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat.com, Nyxoah currently has a consensus rating of Moderate Buy and a consensus price target of $19.40.

Nyxoah Stock Up 2.0 %

NYXH stock opened at $8.50 on Friday. The company has a market cap of $211.99 million, a price-to-earnings ratio of -5.18 and a beta of 1.58. Nyxoah has a twelve month low of $4.00 and a twelve month high of $20.00. The business has a 50 day moving average price of $11.21 and a two-hundred day moving average price of $9.26. The company has a quick ratio of 3.70, a current ratio of 3.94 and a debt-to-equity ratio of 0.13.

Nyxoah (NASDAQ:NYXH) last announced its quarterly earnings results on Tuesday, March 5th. The company reported ($0.41) EPS for the quarter, meeting analysts’ consensus estimates of ($0.41). Nyxoah had a negative net margin of 843.49% and a negative return on equity of 42.14%. The firm had revenue of $1.96 million during the quarter, compared to analysts’ expectations of $2.01 million. Analysts anticipate that Nyxoah will post -1.66 EPS for the current fiscal year.

Institutional Trading of Nyxoah

A hedge fund recently bought a new stake in Nyxoah stock. Iron Triangle Partners LP bought a new position in shares of Nyxoah S.A. (NASDAQ:NYXH) in the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 253,025 shares of the company’s stock, valued at approximately $3,413,000. Nyxoah makes up about 0.3% of Iron Triangle Partners LP’s holdings, making the stock its 28th biggest position.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.